Solara Active Pharma Sciences Ltd

- There is no specific mention of any imminent new fundraising through debt or equity. - The company is focused on reducing existing debt, having reduced debt by about INR153 crores in H1 FY '26 and aiming to reduce it further to around INR446 crores by Q1 FY '27. - Management emphasizes cautious, small bite-sized capex investments primarily for debottlenecking capacity, considering current liquidity constraints. - Regarding the demerger, there is a transfer of INR200 crores debt planned to the new entity, but no immediate additional investment in that business is anticipated due to its longer gestation period. - The company is mindful of its liquidity situation and is actively managing cost and working capital but has not disclosed plans for fresh equity or debt raising in the near term.

- The company is not planning any big capital investments currently due to liquidity constraints. - Capex is focused on small, bite-sized investments primarily aimed at debottlenecking existing capacity. - Ongoing capex projects are designed to be executed on time to increase capacity and support future growth. - No specific capex figures for upcoming periods were provided; investment plans will depend on how existing projects progress. - Regarding the new CRAMs and polymer chemical business (expected after demerger), no immediate investment from Solara is anticipated as this business has a longer gestation period. - The management remains cautious and prudent with capital allocation, focusing on profitable growth and capacity optimization rather than large-scale expansion.

- The company aims for at least 3-4 quarters of growth to demonstrate a strong turnaround. - They have an outlook of approximately 10% sales/revenue growth. - Growth will come from expanding into new markets beyond the US, Europe, and Japan, including Latin America, South Korea, and the Middle East. - Current facility capacity utilization is about 70%, with capacity available to serve new customers. - Incremental sales will be focused on higher-margin and value-added product lines such as ibuprofen derivatives. - The R&D pipeline is being developed, but new product approvals and launches are expected over a 2-3 year time horizon. - Short-term growth will be supported by cost reduction initiatives and debottlenecking of existing capacity. - The business believes that 10% growth rate is sustainable and there is potential to exceed this over the next 2-3 years.

- Solara aims for **sustainable, scalable, and profitable growth** moving forward, focusing on 3-4 quarters of consistent growth to demonstrate a turnaround. - The company targets **10% revenue growth** and **15%-20% EBITDA growth** over the financial year, based on FY '25 as the base. - Margins are expected to improve with a focus on **high gross margin products**, operational cost reductions, and capacity debottlenecking. - New product launches, especially in value-added segments like ibuprofen derivatives, are expected over the next 2-3 years, although they have a gestation period. - Short-term disruptions (like the recent shutdown) are seen as transitory; the underlying fundamentals remain strong with a healthy gross margin ~51%+. - Debt reduction and liquidity improvements are prioritized, which will support profitability in the medium term. - Management is not providing specific capex numbers due to liquidity focus but is making small, strategic investments for capacity expansion.

- Solara Active Pharma Sciences has experienced some short-term disruptions impacting production (Page 12). - Despite a 4-week operational shutdown, management indicated the lost sales orders have not been lost permanently and will be fulfilled in the next two quarters or by Q4 if delayed (Page 12). - The company expects to service deferred revenue/orders by utilizing available capacity in coming quarters, aiming to catch up on production backlog (Page 12). - Facility utilization stands around 70%, with available capacity to cater to new and existing markets (Page 13). - They are optimistic about strengthening order books by expanding into new attractive global markets beyond U.S., Europe, and Japan (Page 13). - Overall, the order book visibility is improving with a focus on sustainable and profitable growth, although some temporary one-offs have affected near-term order fulfillment (Page 15).